BioCentury | Sep 22, 2014
Financial News

PhosImmune completes venture financing

PhosImmune Inc. , Charlottesville, Va. Business: Cancer Date completed: 2014-09-12 Type: Venture financing Raised: $125,000 Investor: Center for Innovative Technology (CIT) GAP Fund Note: The company raised $125,000 in the first tranche of a seed round....
BioCentury | Nov 11, 2013
Emerging Company Profile

SphynKx: Solving the S1P riddle

SphynKx Therapeutics LLC is developing a portfolio of sphingosine kinase inhibitors that can up- or down-regulate blood levels of sphingosine 1-phosphate to treat fibrosis in different organs. The company's lead program focuses on preventing fibrosis...
BioCentury | Sep 30, 2013
Financial News

EVS Glaucoma Therapeutics completes venture financing

EVS Glaucoma Therapeutics LLC , Herndon, Va. Business: Ophthalmic Date completed: 9/11/13 Type: Venture financing Raised: $50,000 Investor: Center for Innovative Technology (CIT) GAP Fund WIR Staff Ophthalmic...
BioCentury | Feb 27, 2012
Financial News

Xdynia completes venture financing

Xdynia LLC , Charlottseville, Va. Business: Neurology Date completed: 2/23/12 Type: Venture financing Raised: $1.3 million Investors: Center for Innovative Technology GAP Fund; and other undisclosed investors Note: The newco raised $50,000 from the Center for...
BioCentury | Feb 27, 2012
Company News

Tau Therapeutics, Xdynia deal

Cancer company Tau Therapeutics launched newco Xdynia to focus on the development of calcium channel T-type inhibitors for neuropathic pain. Tau licensed two libraries of compounds to Xdynia, which plans to select a lead compound...
BioCentury | Feb 24, 2012
Company News

Tau Therapeutics launches new pain company

Cancer company Tau Therapeutics LLC (Charlottesville, Va.) launched newco Xdynia LLC to focus on the development of calcium channel T-type inhibitors for neuropathic pain. Tau licensed two libraries of compounds to Xdynia, which plans to...
Items per page:
1 - 6 of 6
BioCentury | Sep 22, 2014
Financial News

PhosImmune completes venture financing

PhosImmune Inc. , Charlottesville, Va. Business: Cancer Date completed: 2014-09-12 Type: Venture financing Raised: $125,000 Investor: Center for Innovative Technology (CIT) GAP Fund Note: The company raised $125,000 in the first tranche of a seed round....
BioCentury | Nov 11, 2013
Emerging Company Profile

SphynKx: Solving the S1P riddle

SphynKx Therapeutics LLC is developing a portfolio of sphingosine kinase inhibitors that can up- or down-regulate blood levels of sphingosine 1-phosphate to treat fibrosis in different organs. The company's lead program focuses on preventing fibrosis...
BioCentury | Sep 30, 2013
Financial News

EVS Glaucoma Therapeutics completes venture financing

EVS Glaucoma Therapeutics LLC , Herndon, Va. Business: Ophthalmic Date completed: 9/11/13 Type: Venture financing Raised: $50,000 Investor: Center for Innovative Technology (CIT) GAP Fund WIR Staff Ophthalmic...
BioCentury | Feb 27, 2012
Financial News

Xdynia completes venture financing

Xdynia LLC , Charlottseville, Va. Business: Neurology Date completed: 2/23/12 Type: Venture financing Raised: $1.3 million Investors: Center for Innovative Technology GAP Fund; and other undisclosed investors Note: The newco raised $50,000 from the Center for...
BioCentury | Feb 27, 2012
Company News

Tau Therapeutics, Xdynia deal

Cancer company Tau Therapeutics launched newco Xdynia to focus on the development of calcium channel T-type inhibitors for neuropathic pain. Tau licensed two libraries of compounds to Xdynia, which plans to select a lead compound...
BioCentury | Feb 24, 2012
Company News

Tau Therapeutics launches new pain company

Cancer company Tau Therapeutics LLC (Charlottesville, Va.) launched newco Xdynia LLC to focus on the development of calcium channel T-type inhibitors for neuropathic pain. Tau licensed two libraries of compounds to Xdynia, which plans to...
Items per page:
1 - 6 of 6